204 related articles for article (PubMed ID: 12375882)
1. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
2. Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
McCluskey A; Walkom C; Bowyer MC; Ackland SP; Gardiner E; Sakoff JA
Bioorg Med Chem Lett; 2001 Nov; 11(22):2941-6. PubMed ID: 11677131
[TBL] [Abstract][Full Text] [Related]
3. Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
Hill TA; Stewart SG; Sauer B; Gilbert J; Ackland SP; Sakoff JA; McCluskey A
Bioorg Med Chem Lett; 2007 Jun; 17(12):3392-7. PubMed ID: 17451951
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin).
Baba Y; Hirukawa N; Tanohira N; Sodeoka M
J Am Chem Soc; 2003 Aug; 125(32):9740-9. PubMed ID: 12904040
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
Thaqi A; Scott JL; Gilbert J; Sakoff JA; McCluskey A
Eur J Med Chem; 2010 May; 45(5):1717-23. PubMed ID: 20153915
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.
Shan HB; Cai YC; Liu Y; Zeng WN; Chen HX; Fan BT; Liu XH; Xu ZL; Wang B; Xian LJ
Anticancer Drugs; 2006 Sep; 17(8):905-11. PubMed ID: 16940800
[TBL] [Abstract][Full Text] [Related]
7. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
McCluskey A; Bowyer MC; Collins E; Sim ATR ; Sakoff JA; Baldwin ML
Bioorg Med Chem Lett; 2000 Aug; 10(15):1687-90. PubMed ID: 10937725
[TBL] [Abstract][Full Text] [Related]
8. Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition.
Hill TA; Stewart SG; Gordon CP; Ackland SP; Gilbert J; Sauer B; Sakoff JA; McCluskey A
ChemMedChem; 2008 Dec; 3(12):1878-92. PubMed ID: 19025735
[TBL] [Abstract][Full Text] [Related]
9. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
10. Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode.
Baba Y; Hirukawa N; Sodeoka M
Bioorg Med Chem; 2005 Sep; 13(17):5164-70. PubMed ID: 15951185
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.
Sakoff JA; Ackland SP; Baldwin ML; Keane MA; McCluskey A
Invest New Drugs; 2002 Feb; 20(1):1-11. PubMed ID: 12003183
[TBL] [Abstract][Full Text] [Related]
12. The first two cantharidin analogues displaying PP1 selectivity.
McCluskey A; Keane MA; Walkom CC; Bowyer MC; Sim AT; Young DJ; Sakoff JA
Bioorg Med Chem Lett; 2002 Feb; 12(3):391-3. PubMed ID: 11814804
[TBL] [Abstract][Full Text] [Related]
13. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation.
Rice RL; Rusnak JM; Yokokawa F; Yokokawa S; Messner DJ; Boynton AL; Wipf P; Lazo JS
Biochemistry; 1997 Dec; 36(50):15965-74. PubMed ID: 9398331
[TBL] [Abstract][Full Text] [Related]
14. Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin.
To KK; Wang X; Yu CW; Ho YP; Au-Yeung SC
Bioorg Med Chem; 2004 Sep; 12(17):4565-73. PubMed ID: 15358284
[TBL] [Abstract][Full Text] [Related]
15. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.
McCluskey A; Ackland SP; Bowyer MC; Baldwin ML; Garner J; Walkom CC; Sakoff JA
Bioorg Chem; 2003 Feb; 31(1):68-79. PubMed ID: 12697169
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin.
Bertini I; Calderone V; Fragai M; Luchinat C; Talluri E
J Med Chem; 2009 Aug; 52(15):4838-43. PubMed ID: 19601647
[TBL] [Abstract][Full Text] [Related]
17. Cantharidin impedes the activity of protein serine/threonine phosphatase in Plutella xylostella.
Chen X; Liu J; Zhang Y
Mol Biosyst; 2014 Feb; 10(2):240-50. PubMed ID: 24253262
[TBL] [Abstract][Full Text] [Related]
18. [Protein phosphatase 2A: its structure, function and activity regulation].
Liu WJ; Shen Y; Ding J
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Feb; 35(2):105-12. PubMed ID: 12545214
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of protein phosphatase 2A activity by selective electrophile alkylation damage.
Codreanu SG; Adams DG; Dawson ES; Wadzinski BE; Liebler DC
Biochemistry; 2006 Aug; 45(33):10020-9. PubMed ID: 16906760
[TBL] [Abstract][Full Text] [Related]
20. Phosphatases as targets for cancer treatment.
Lazo JS; Wipf P
Curr Opin Investig Drugs; 2009 Dec; 10(12):1297-304. PubMed ID: 19943201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
